1.13
-0.05 (-4.24%)
| Previous Close | 1.18 |
| Open | 1.15 |
| Volume | 58,587 |
| Avg. Volume (3M) | 1,301,281 |
| Market Cap | 11,331,668 |
| Price / Book | 1.00 |
| 52 Weeks Range |
| Operating Margin (TTM) | -2,518.17% |
| Diluted EPS (TTM) | -0.350 |
| Quarterly Revenue Growth (YOY) | 56.80% |
| Total Debt/Equity (MRQ) | 25.43% |
| Current Ratio (MRQ) | 0.080 |
| Operating Cash Flow (TTM) | -1.07 M |
| Return on Assets (TTM) | -8.04% |
| Return on Equity (TTM) | -21.00% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Gelteq Limited | - | - |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -2.5 |
| Average | 0.25 |
|
Gelteq Ltd is a clinical and science-based company that is focused on developing and commercializing white-label gel-based delivery solutions to preserve the simplicity, accessibility and efficacy of oral delivery without the impediments traditionally associated with other oral delivery methods, with prescription drugs, nutraceuticals, pet care, and other products. It is engaged in the development and testing of a gel-based delivery system for humans and pets. Its principal products are edible gels. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| % Held by Insiders | 60.36% |
| % Held by Institutions | 1.11% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 23 Oct 2025 | Announcement | Gelteq Announces Commencement of Preclinical Trial Targeting Oil Soluble Drug Market with Novel Delivery Platform |
| 09 Oct 2025 | Announcement | Gelteq Announces New Product Development Agreement with Melbourne Health for Novel Bowel Polyp Growth Reduction Compound |
| 12 Sep 2025 | Announcement | Gelteq Technology Powers U.S. Product Launches of its Nutraceutical Products for Partner |
| 05 Sep 2025 | Announcement | Gelteq Announces Commencement of Preclinical Trial for Novel Gel-Based Antihistamine Formulation Targeting Allergy Market |
| 04 Sep 2025 | Announcement | Healthy Extracts Builds Upon Record Q2 Results and Transformative Merger with Launch of New Revolutionary Hydration and Sugar Metabolism Gel-Packs |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |